User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Therapeutic recommendations for early stage Hodgkin lymphomas.

Primary tabs

download
  • Open access
  • PDF
  • 145.38 K
Depaus, Julien [UCL] Delcourt, Anne André, Marc [UCL]

Combined modality treatment has been the standard option for the treatment of early stage Hodgkin lymphoma for several decades. Because of the high success rate and the risk of late toxicities, recent clinical trials have focused on reducing the treatment burden. Field and dose of radiotherapy, and number of cycles of chemotherapy have been successfully reduced, particularly for favourable early stage patients. However, the impact of these treatment reductions on the rate of secondary malignancies remains still unclear. Positron emission tomography-computed tomography (PET-CT) scanning has emerged as a very important tool for disease staging and end of treatment assessment. Interestingly, a PET performed after 2 cycles of ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) has been correlated with final outcome and was recently evaluated in a randomized clinical trial to evaluate individualized therapy based on PET response after 2 or 3 cycles of ABVD. These trials aimed to identify good prognosis (early PET-negative) patients who could be spared radiotherapy, but also patients with a bad prognosis (early PET-positive) who need more intensive treatment. More recently, new drugs, such as brentuximab vedotin and checkpoint inhibitors, have shown efficacy in relapsed/refractory patients and are currently under evaluation in early stage patients.

Document type Article de périodique (Journal article) – Synthèse de littérature
Access type Accès libre
Publication date 2019
Language Anglais
Journal information "British journal of haematology" - Vol. 184, no. 1, p. 9-16 (2019)
Peer reviewed yes
Publisher Wiley-Blackwell ((United Kingdom) Oxford)
issn 0007-1048
e-issn 1365-2141
Publication status Publié
Affiliations UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie
UCL - SSS/IREC/MONT - Pôle Mont Godinne
UCL - (MGD) Service d'hématologie
Keywords Hodgkin lymphoma ; modality treatment ; radiotherapy
Links
  1. Aleman Berthe M.P., van den Belt-Dusebout Alexandra W., Klokman Willem J., van’t Veer Mars B., Bartelink Harry, van Leeuwen Flora E., Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin’s Disease, 10.1200/jco.2003.07.131
  2. André Marc P.E., Girinsky Théodore, Federico Massimo, Reman Oumédaly, Fortpied Catherine, Gotti Manuel, Casasnovas Olivier, Brice Pauline, van der Maazen Richard, Re Alessandro, Edeline Véronique, Fermé Christophe, van Imhoff Gustaaf, Merli Francesco, Bouabdallah Réda, Sebban Catherine, Specht Lena, Stamatoullas Aspasia, Delarue Richard, Fiaccadori Valeria, Bellei Monica, Raveloarivahy Tiana, Versari Annibale, Hutchings Martin, Meignan Michel, Raemaekers John, Early Positron Emission Tomography Response–Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial, 10.1200/jco.2016.68.6394
  3. Baxstrom K., Peterson B. A., Lee C., Vogel R. I., Blaes A. H., A pilot investigation on impact of participation in a long-term follow-up clinic (LTFU) on breast cancer and cardiovascular screening among women who received chest radiation for Hodgkin lymphoma, 10.1007/s00520-018-4072-x
  4. Behringer Karolin, Goergen Helen, Hitz Felicitas, Zijlstra Josée M, Greil Richard, Markova Jana, Sasse Stephanie, Fuchs Michael, Topp Max S, Soekler Martin, Mathas Stephan, Meissner Julia, Wilhelm Martin, Koch Peter, Lindemann Hans-Walter, Schalk Enrico, Semrau Robert, Kriz Jan, Vieler Tom, Bentz Martin, Lange Elisabeth, Mahlberg Rolf, Hassler Andre, Vogelhuber Martin, Hahn Dennis, Mezger Jörg, Krause Stefan W, Skoetz Nicole, Böll Boris, von Tresckow Bastian, Diehl Volker, Hallek Michael, Borchmann Peter, Stein Harald, Eich Hans, Engert Andreas, Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial, 10.1016/s0140-6736(14)61469-0
  5. Chen Robert, Zinzani Pier Luigi, Fanale Michelle A., Armand Philippe, Johnson Nathalie A., Brice Pauline, Radford John, Ribrag Vincent, Molin Daniel, Vassilakopoulos Theodoros P., Tomita Akihiro, von Tresckow Bastian, Shipp Margaret A., Zhang Yinghua, Ricart Alejandro D., Balakumaran Arun, Moskowitz Craig H., , Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma, 10.1200/jco.2016.72.1316
  6. Cheson Bruce D., Fisher Richard I., Barrington Sally F., Cavalli Franco, Schwartz Lawrence H., Zucca Emanuele, Lister T. Andrew, Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification, 10.1200/jco.2013.54.8800
  7. Cutter David J., Schaapveld Michael, Darby Sarah C., Hauptmann Michael, van Nimwegen Frederika A., Krol Augustinus D. G., Janus Cecile P. M., van Leeuwen Flora E., Aleman Berthe M. P., Risk for Valvular Heart Disease After Treatment for Hodgkin Lymphoma, 10.1093/jnci/djv008
  8. Eich Hans Theodor, Diehl Volker, Görgen Helen, Pabst Thomas, Markova Jana, Debus Jürgen, Ho Anthony, Dörken Bernd, Rank Andreas, Grosu Anca-Ligia, Wiegel Thomas, Karstens Johann Hinrich, Greil Richard, Willich Normann, Schmidberger Heinz, Döhner Hartmut, Borchmann Peter, Müller-Hermelink Hans-Konrad, Müller Rolf-Peter, Engert Andreas, Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial, 10.1200/jco.2010.29.8018
  9. Eichenauer D A, Aleman B M P, André M, Federico M, Hutchings M, Illidge T, Engert A, Ladetto M, , Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†, 10.1093/annonc/mdy080
  10. El-Galaly Tarec Christoffer, d'Amore Francesco, Mylam Karen Juul, de Nully Brown Peter, Bøgsted Martin, Bukh Anne, Specht Lena, Loft Annika, Iyer Victor, Hjorthaug Karin, Nielsen Anne Lerberg, Christiansen Ilse, Madsen Charlotte, Johnsen Hans-Erik, Hutchings Martin, Routine Bone Marrow Biopsy Has Little or No Therapeutic Consequence for Positron Emission Tomography/Computed Tomography–Staged Treatment-Naive Patients With Hodgkin Lymphoma, 10.1200/jco.2012.42.4036
  11. Engert Andreas, Schiller Petra, Josting Andreas, Herrmann Richard, Koch Peter, Sieber Markus, Boissevain Friederike, de Wit Maike, Mezger Jörg, Dühmke Eckhart, Willich Normann, Müller Rolf-Peter, Schmidt Bernhard F., Renner Helmut, Müller-Hermelink Hans Konrad, Pfistner Beate, Wolf Jürgen, Hasenclever Dirk, Löffler Markus, Diehl Volker, Involved-Field Radiotherapy Is Equally Effective and Less Toxic Compared With Extended-Field Radiotherapy After Four Cycles of Chemotherapy in Patients With Early-Stage Unfavorable Hodgkin’s Lymphoma: Results of the HD8 Trial of the German Hodgkin’s Lymphoma Study Group, 10.1200/jco.2003.03.023
  12. Engert Andreas, Franklin Jeremy, Eich Hans Theodor, Brillant Corinne, Sehlen Susanne, Cartoni Claudio, Herrmann Richard, Pfreundschuh Michael, Sieber Markus, Tesch Hans, Franke Astrid, Koch Peter, de Wit Maike, Paulus Ursula, Hasenclever Dirk, Loeffler Markus, Müller Rolf-Peter, Müller-Hermelink Hans Konrad, Dühmke Eckhart, Diehl Volker, Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy Is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final Results of the GHSG HD7 Trial, 10.1200/jco.2006.07.0482
  13. Engert Andreas, Plütschow Annette, Eich Hans Theodor, Lohri Andreas, Dörken Bernd, Borchmann Peter, Berger Bernhard, Greil Richard, Willborn Kay C., Wilhelm Martin, Debus Jürgen, Eble Michael J., Sökler Martin, Ho Antony, Rank Andreas, Ganser Arnold, Trümper Lorenz, Bokemeyer Carsten, Kirchner Hartmut, Schubert Jörg, Král Zdenek, Fuchs Michael, Müller-Hermelink Hans-Konrad, Müller Rolf-Peter, Diehl Volker, Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma, 10.1056/nejmoa1000067
  14. Fermé Christophe, Eghbali Houchingue, Meerwaldt Jacobus H., Rieux Chantal, Bosq Jacques, Berger Françoise, Girinsky Théodore, Brice Pauline, van't Veer Mars B., Walewski Jan A., Lederlin Pierre, Tirelli Umberto, Carde Patrice, Van Den Neste Eric, Gyan Emmanuel, Monconduit Mathieu, Diviné Marine, Raemaekers John M.M., Salles Gilles, Noordijk Evert M., Creemers Geert-Jan, Gabarre Jean, Hagenbeek Anton, Reman Oumédaly, Blanc Michel, Thomas José, Vié Brigitte, Kluin-Nelemans Johanna C., Viseu Fernando, Baars Joke W., Poortmans Philip, Lugtenburg Pieternella J., Carrie Christian, Jaubert Jérôme, Henry-Amar Michel, Chemotherapy plus Involved-Field Radiation in Early-Stage Hodgkin's Disease, 10.1056/nejmoa064601
  15. Fermé Christophe, Thomas José, Brice Pauline, Casasnovas Olivier, Vranovsky Andrej, Bologna Serge, Lugtenburg Pieternella J., Bouabdallah Réda, Carde Patrice, Sebban Catherine, Eghbali Houchingue, Salles Gilles, van Imhoff Gustaaf W., Thyss Antoine, Noordijk Evert M., Reman Oumédaly, Lybeert Marnix L.M., Janvier Maud, Spina Michele, Audhuy Bruno, Raemaekers John M.M., Delarue Richard, Anglaret Bruno, de Weerdt Okke, Marjanovic Zora, Tersteeg Robbert J.H.A., de Jong Daphne, Brière Josette, Henry-Amar Michel, ABVD or BEACOPP baseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)–Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial, 10.1016/j.ejca.2017.05.005
  16. Gallamini Andrea, Hutchings Martin, Rigacci Luigi, Specht Lena, Merli Francesco, Hansen Mads, Patti Caterina, Loft Annika, Di Raimondo Francesco, D'Amore Francesco, Biggi Alberto, Vitolo Umberto, Stelitano Caterina, Sancetta Rosario, Trentin Livio, Luminari Stefano, Iannitto Emilio, Viviani Simonetta, Pierri Ivana, Levis Alessandro, Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study, 10.1200/jco.2007.11.6525
  17. Hahn Ezra, Jiang Haiyan, Ng Angela, Bashir Shaheena, Ahmed Sameera, Tsang Richard, Sun Alexander, Gospodarowicz Mary, Hodgson David, Late Cardiac Toxicity After Mediastinal Radiation Therapy for Hodgkin Lymphoma: Contributions of Coronary Artery and Whole Heart Dose-Volume Variables to Risk Prediction, 10.1016/j.ijrobp.2017.03.026
  18. Hoppe Richard T., Advani Ranjana H., Ai Weiyun Z., Ambinder Richard F., Aoun Patricia, Bello Celeste M., Benitez Cecil M., Bernat Karl, Bierman Philip J., Blum Kristie A., Chen Robert, Dabaja Bouthaina, Forero Andres, Gordon Leo I., Hernandez-Ilizaliturri Francisco J., Hochberg Ephraim P., Huang Jiayi, Johnston Patrick B., Kaminski Mark S., Kenkre Vaishalee P., Khan Nadia, Maloney David G., Mauch Peter M., Metzger Monika, Moore Joseph O., Morgan David, Moskowitz Craig H., Mulroney Carolyn, Poppe Matthew, Rabinovitch Rachel, Seropian Stuart, Smith Mitchell, Winter Jane N., Yahalom Joachim, Burns Jennifer, Ogba Ndiya, Sundar Hema, Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology, 10.6004/jnccn.2017.0064
  19. Juweid Malik E., Stroobants Sigrid, Hoekstra Otto S., Mottaghy Felix M., Dietlein Markus, Guermazi Ali, Wiseman Gregory A., Kostakoglu Lale, Scheidhauer Klemens, Buck Andreas, Naumann Ralph, Spaepen Karoline, Hicks Rodney J., Weber Wolfgang A., Reske Sven N., Schwaiger Markus, Schwartz Lawrence H., Zijlstra Josee M., Siegel Barry A., Cheson Bruce D., Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma, 10.1200/jco.2006.08.2305
  20. Maraldo M.V., Jørgensen M., Brodin N.P., Aznar M.C., Vogelius I.R., Petersen P.M., Berthelsen A.K., Christensen C.B., Hjalgrim L.L., Specht L., The impact of involved node, involved field and mantle field radiotherapy on estimated radiation doses and risk of late effects for pediatric patients with Hodgkin lymphoma : Radiotherapy for Pediatric Hodgkin Lymphoma, 10.1002/pbc.24861
  21. Meyer Ralph M., Gospodarowicz Mary K., Connors Joseph M., Pearcey Robert G., Wells Woodrow A., Winter Jane N., Horning Sandra J., Dar A. Rashid, Shustik Chaim, Stewart Douglas A., Crump Michael, Djurfeldt Marina S., Chen Bingshu E., Shepherd Lois E., ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma, 10.1056/nejmoa1111961
  22. Radford John, Illidge Tim, Counsell Nicholas, Hancock Barry, Pettengell Ruth, Johnson Peter, Wimperis Jennie, Culligan Dominic, Popova Bilyana, Smith Paul, McMillan Andrew, Brownell Alison, Kruger Anton, Lister Andrew, Hoskin Peter, O’Doherty Michael, Barrington Sally, Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma, 10.1056/nejmoa1408648
  23. Sasse Stephanie, Bröckelmann Paul J., Goergen Helen, Plütschow Annette, Müller Horst, Kreissl Stefanie, Buerkle Carolin, Borchmann Sven, Fuchs Michael, Borchmann Peter, Diehl Volker, Engert Andreas, Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials, 10.1200/jco.2016.70.9410
  24. Schaapveld Michael, Aleman Berthe M.P., van Eggermond Anna M., Janus Cécile P.M., Krol Augustinus D.G., van der Maazen Richard W.M., Roesink Judith, Raemaekers John M.M., de Boer Jan Paul, Zijlstra Josée M., van Imhoff Gustaaf W., Petersen Eefke J., Poortmans Philip M.P., Beijert Max, Lybeert Marnix L., Mulder Ina, Visser Otto, Louwman Marieke W.J., Krul Inge M., Lugtenburg Pieternella J., van Leeuwen Flora E., Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma, 10.1056/nejmoa1505949
  25. Simontacchi Gabriele, Filippi Andrea Riccardo, Ciammella Patrizia, Buglione Michela, Saieva Calogero, Magrini Stefano Maria, Livi Lorenzo, Iotti Cinzia, Botto Barbara, Vaggelli Luca, Re Alessandro, Merli Francesco, Ricardi Umberto, Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy, 10.1016/j.ijrobp.2015.04.021
  26. Spina Valeria, Bruscaggin Alessio, Cuccaro Annarosa, Martini Maurizio, Di Trani Martina, Forestieri Gabriela, Manzoni Martina, Condoluci Adalgisa, Arribas Alberto, Terzi-Di-Bergamo Lodovico, Locatelli Silvia Laura, Cupelli Elisa, Ceriani Luca, Moccia Alden A., Stathis Anastasios, Nassi Luca, Deambrogi Clara, Diop Fary, Guidetti Francesca, Cocomazzi Alessandra, Annunziata Salvatore, Rufini Vittoria, Giordano Alessandro, Neri Antonino, Boldorini Renzo, Gerber Bernhard, Bertoni Francesco, Ghielmini Michele, Stüssi Georg, Santoro Armando, Cavalli Franco, Zucca Emanuele, Larocca Luigi Maria, Gaidano Gianluca, Hohaus Stefan, Carlo-Stella Carmelo, Rossi Davide, Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma, 10.1182/blood-2017-11-812073
  27. Straus David J., Jung Sin-Ho, Pitcher Brandelyn, Kostakoglu Lale, Grecula John C., Hsi Eric D., Schöder Heiko, Popplewell Leslie L., Chang Julie E., Moskowitz Craig H., Wagner-Johnston Nina, Leonard John P., Friedberg Jonathan W., Kahl Brad S., Cheson Bruce D., Bartlett Nancy L., CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET, 10.1182/blood-2018-01-827246
  28. Thomas José, Fermé Christophe, Noordijk Evert M., Morschhauser Franck, Girinsky Théodore, Gaillard Isabelle, Lugtenburg Pieternella J., André Marc, Lybeert Marnix L.M., Stamatoullas Aspasia, Beijert Max, Hélias Philippe, Eghbali Houchingue, Gabarre Jean, van der Maazen Richard W.M., Jaubert Jérôme, Bouabdallah Krimo, Boulat Olivier, Roesink Judith M., Christian Bernard, Ong Francisca, Bordessoule Dominique, Tertian Gérard, Gonzalez Hugo, Vranovsky Andrej, Quittet Philippe, Tirelli Umberto, de Jong Daphne, Audouin Josée, Aleman Berthe M.P., Henry-Amar Michel, Comparison of 36 Gy, 20 Gy, or No Radiation Therapy After 6 Cycles of EBVP Chemotherapy and Complete Remission in Early-Stage Hodgkin Lymphoma Without Risk Factors: Results of the EORT-GELA H9-F Intergroup Randomized Trial, 10.1016/j.ijrobp.2017.10.015
  29. von Tresckow Bastian, Plütschow Annette, Fuchs Michael, Klimm Beate, Markova Jana, Lohri Andreas, Kral Zdenek, Greil Richard, Topp Max S., Meissner Julia, Zijlstra Josée M., Soekler Martin, Stein Harald, Eich Hans T., Mueller Rolf P., Diehl Volker, Borchmann Peter, Engert Andreas, Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial, 10.1200/jco.2011.38.5807
  30. Younes Anas, Gopal Ajay K., Smith Scott E., Ansell Stephen M., Rosenblatt Joseph D., Savage Kerry J., Ramchandren Radhakrishnan, Bartlett Nancy L., Cheson Bruce D., de Vos Sven, Forero-Torres Andres, Moskowitz Craig H., Connors Joseph M., Engert Andreas, Larsen Emily K., Kennedy Dana A., Sievers Eric L., Chen Robert, Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma, 10.1200/jco.2011.38.0410
  31. Younes Anas, Santoro Armando, Shipp Margaret, Zinzani Pier Luigi, Timmerman John M, Ansell Stephen, Armand Philippe, Fanale Michelle, Ratanatharathorn Voravit, Kuruvilla John, Cohen Jonathon B, Collins Graham, Savage Kerry J, Trneny Marek, Kato Kazunobu, Farsaci Benedetto, Parker Susan M, Rodig Scott, Roemer Margaretha G M, Ligon Azra H, Engert Andreas, Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial, 10.1016/s1470-2045(16)30167-x
Bibliographic reference Depaus, Julien ; Delcourt, Anne ; André, Marc. Therapeutic recommendations for early stage Hodgkin lymphomas.. In: British journal of haematology, Vol. 184, no. 1, p. 9-16 (2019)
Permanent URL http://hdl.handle.net/2078.1/208151